A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

Part of paid clinical trials in Denver, Colorado.

Sponsor
Kumquat Biosciences Inc.
Study ID
NCT06507306
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Solid Tumor, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

Key Dates

First listed
Jul 18, 2024
Start date
Jun 3, 2024
Status verified
Jul 2026
Primary completion
Jul 31, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
92 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Monotherapy Dose Escalation
  • Experimental: Combo Therapy Dose Escalation
  • Experimental: Combo Therapy Dose Expansion - RP2D
  • Experimental: Combo Therapy Dose Expansion - RP2D-1
  • Experimental: Combo Therapy Dose Expansion OBD

Primary Outcome Measure

Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1) [ Time Frame: 28 Days ]

Locations (9)

Find similar trials in Denver, CO

Related Studies